null

null

null

null

null

null

null

null

null

0.14x Total Debt / Equity (Conservative)

Low direct sensitivity; ~$150M cash, minimal debt post-IPO, but rising rates pressure growth-stock valuation multiples significantly

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Taiwan semiconductor fabrication for robotics chips; single-source precision optical components from Japanese/German suppliers

Early international stage; EU (EUR), Japan (JPY), Australia (AUD) are top markets with moderate devaluation risk; EUR most material

~85% US revenue; EUR exposure ~10%, JPY ~3%; sovereign devaluation risk manageable but EUR/USD swings impact reported international revenue

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Aquabeam laser system relies on non-substitutable water jet/laser components; single-source robotics subsystem suppliers create >30% input cost dependency

Cloud disruption moderate risk; AQUABEAM capital system and procedure data likely on AWS/Azure but core value is physical hardware, not cloud-dependent

Handpiece consumable model (razors-and-blades); 30-day cloud termination disrupts data analytics/remote monitoring but not core surgical revenue

Minimal API coupling risk; proprietary embedded software in AQUABEAM robot creates high institutional switching cost; not API-dependent externally

Near-zero Howey risk; revenue from capital equipment sales and single-use handpiece consumables—purely commercial medical device transactions

Very High

Moderate GDPR exposure as EU expansion grows; patient procedure data triggers medical-data compliance; HIPAA primary US obligation; CCPA limited exposure

Low current antitrust risk; nascent market share in BPH surgery; Intuitive Surgical dominance in robotics creates benchmark scrutiny but PROCEPT too small to trigger

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~70% transactional (handpiece consumables per procedure), ~20% capital equipment, ~10% service contracts; recurring consumable stream grows with installed base

Razor-and-blade: AQUABEAM system placement drives recurring single-use handpiece revenue (~$3,500–$4,500 per procedure consumable attach rate)

Capital system ~$500K–$600K; handpiece ~$1,500–$2,000 per unit; price compression risk low near-term given clinical differentiation and limited competition

7/10; strong differentiation vs. TURP and laser alternatives; pricing power constrained by hospital GPO negotiations and reimbursement rate caps

63.7% Gross Margin (Premium (>60%))

No free-rider problem; proprietary consumables locked to AQUABEAM platform; churn risk is hospital budget cuts or competitive robotic entrants

Revenue growth is sublinear to headcount at scale; field clinical specialists scale with procedures but manufacturing and R&D costs are largely fixed

Marginal cost of incremental procedure revenue is primarily handpiece COGS (~40–50% gross margin); capital deployment drives high-leverage consumable pull-through

Not applicable; direct sales model, no franchise network

At 10x scale (~$1B revenue), CAC per hospital likely declines 40–50% via brand recognition; LTV/CAC improves significantly with consumable attach rate compounding

Weak direct network effects; indirect effect via clinical data flywheel improving AI-guided robotics outcomes; not a true marketplace network effect

-18.8% Return on Assets (Negative equity)

Tier 3 moderate resilience; BPH procedures partially elective/deferrable; hospital capex cuts in recessions delay system placements materially

US hospitals and ambulatory surgery centers performing urological procedures; no single customer >5% of revenue

Academic medical centers and high-volume urology group practices; international hospital systems in EU and Asia-Pacific secondary segment

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

3.0% CapEx / Revenue (Low-CapEx Asset-Light)

0001588978

PRCT